Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Delgocitinib cream in Discoid Lupus Erythematosus
NCT03958955Phase 2Terminated
- Sponsor
- LEO Pharma
- Start
- Jul 2019
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in discoid lupus erythematosus (DLE) comparing Delgocitinib cream 20 mg/g with Delgocitinib cream vehicle (2 arms). Primary endpoint: Target Lesions With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at 6 weeks. Started Jul 2019; status: terminated.
02
Drugs
delgocitinib
03
Conditions
discoid lupus erythematosus (DLE)
Beyond the preview
Go deeper on NCT03958955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03958955.